“It is time to offer genetic screening of BRCA1 and BRCA2 genes to every women”
Dr. Marie-Claire King (discoverer of BRCA1 gene)
Ovarian cancer genetics
- BRCA1 ir BRCA2 genai
- MMR genai (MLH1, MSH2, MSH6, EPCAM, PMS2)
- BRIP1
- RAD51C
- RAD51D
- TP53
- STK11
- Polimorfizmai (SNP)
- Nežinomi genetiniai veiksniai
- BRCA1 ir BRCA2 genai
- MMR genai (MLH1, MSH2, MSH6, EPCAM, PMS2)
- BRIP1
- RAD51C
- RAD51D
- TP53
- STK11
- Polimorfizmai (SNP)
- Nežinomi genetiniai veiksniai
Ovarian cancer (OC) is the main cause of death from gynecologic tumors of young women in developed countries. Ovarian cancer is diagnosed in an estimated 20000 women in the U.S. and 7300 the U.K. This makes ovarian cancer the 5th most common cancer in women. Ovarian cancer (especially epithelial serous carcinoma) is one of the most heritable cancer types since more than 20-25% OC are caused by inherited mutations in cancer predisposition genes. Moreover, when there is a significant history of OC in a family, the hereditary component is almost guaranteed.
There are at least 19 known genes which mutations confers increased breast and ovarian cancer risk. BRCA1 and BRCA2 gene mutations are the main and most important breast and ovarian cancer genetic risk factors, which testing is recommended for ALL WOMEN. Regardless of your family history, only comprehensive testing can determine if you carry a gene mutation.
BRCA1/2 breast and ovarian cancer risk
Comprehensive oncogenetic test of gene panels using modern next generation sequencing (NGS) technology is the most precise method for genetic ovarian cancer risk assessment.
A single comprehensive genetic ONCORISK61 test evaluates cancer-predisposing mutations in 61 genes at once, at least 19 of which are associated with increased ovarian and breast cancer risk (mutations in other genes are associated with other cancer risks, such as uterine, colorectal, stomach, pancreas, skin, prostate): BRCA1, BRCA2, TP53, PTEN, STK11, CDH1, PALB2, ATM, BRIP1, BARD1, CHEK2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2, EPCAM, MUTYH, APC, BMPR1A, SMAD4, GREM1, POLD1, POLE, NBN, SMARCA4, NF1, MITF, BAP1, CDKN2A, CDK4.
0%
BRCA1: Ovarian cancer risk
0%
BRCA1: Breast cancer risk
0%
BRCA1/2 genes account for 80% of hereditary ovarian cancer
Effective hereditary cancer risk reduction methods exist
Oncogenetic testing helps to evaluate individual cancer risk and choose the most appropriate health care. Established management, screening and prevention options help to avoid cancer or detect changes at the earliest and the most curable stages.
0m.
Onset of breast MRI screening
0%
Ovarian cancer risk reduction (after salpingoophorectomy)
0%
Breast cancer risk reduction (after salpingoophorectomy)
2200€
Full BRCA1 and BRCA2 mutation testing (including counselling)
Experienced oncogeneticist will assess your individual cancer risk and prescribe appropriate genetic tests
Ramūnas Janavičius
Med. m. Dr., gyd. genetikas